The role of Kolaviron, a bioflavonoid from Garcinia kola, in the management of cardiovascular diseases: A systematic review
- PMID: 38449600
- PMCID: PMC10915569
- DOI: 10.1016/j.heliyon.2024.e27333
The role of Kolaviron, a bioflavonoid from Garcinia kola, in the management of cardiovascular diseases: A systematic review
Abstract
While the cardiovascular effects of Kolaviron (KV) and Garcinia kola (GK) are documented in the literature, a thorough search through literature revealed a fragmentation of information on the effect of KV and GK on cardiovascular diseases (CVDs). This systematic review aims to evaluate and summarize preclinical or clinical evidence on the effect of KV and GK on CVDs. Using the PRISMA guidelines, a systematic literature search was conducted in five medical databases (PubMed, Cochrane, EMBASE, CINAHL, and Web of Science). Inclusion criteria included both in vivo and in vitro studies related to CVDs. Eligible studies included those in which specific clinical parameters, CVD biomarkers, or voltage-gated channel effects were reported. The quality of the included studies was assessed using a modified Collaborative Approach to Meta-Analysis and Review of Animal Data from the Experimental Studies (CAMARADE) checklist. A total of 22 studies were included in this systematic review. The median and mean values of the included studies' quality scores were 6 and 5.864 ± 0.296, respectively. The results from the quality assessment of included studies validate their suitability, usefulness, and fit. Based on this systematic review, the effect of KV and GK on CVDs can be divided into eight emerging trends: (1) Anti-hypertensive/Blood pressure lowering effect; (2) Lipid profile improvement effect (3) Anti-atherosclerotic effect; (4) Anti-thrombotic effect; (5) Cardioprotection; (6) Vasodilatory effect; (7) Antioxidant effects; and (8) Genetic expression and therapeutic target for cardiovascular dysfunction. From this systematic review, it can be concluded that KV is helpful in managing CVD risk factors such as hypertension and high lipids/cholesterol. Several included studies in this review demonstrated the antihypertensive, lipid improvement, antioxidant, and signaling pathway modulation effects of KV. This potentially makes KV a good therapeutic target for the management of CVDs.
Keywords: Antioxidants; Cardiovascular diseases; Flavonoid; Garcinia kola; Hypertension; Kolaviron.
© 2024 Published by Elsevier Ltd.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Kolaviron and Garcinia kola Seed Extract Protect Against Ischaemia/Reperfusion Injury on Isolated Rat Heart.Drug Res (Stuttg). 2018 May;68(5):286-295. doi: 10.1055/s-0043-123686. Epub 2018 Jan 8. Drug Res (Stuttg). 2018. PMID: 29310144
-
Ameliorative effect of Kolaviron, an extract of Garcinia kola seeds, on induced hypertension.J Complement Integr Med. 2021 May 11;19(1):37-46. doi: 10.1515/jcim-2020-0354. J Complement Integr Med. 2021. PMID: 33977689
-
Kolaviron, Biflavonoid Complex from the Seed of Garcinia kola Attenuated Angiotensin II- and Lypopolysaccharide-induced Vascular Smooth Muscle Cell Proliferation and Nitric Oxide Production.Pharmacognosy Res. 2016 Mar;8(Suppl 1):S50-5. doi: 10.4103/0974-8490.178647. Pharmacognosy Res. 2016. PMID: 27114693 Free PMC article.
-
A review on garcinia kola heckel: traditional uses, phytochemistry, pharmacological activities, and toxicology.Biomarkers. 2022 Mar;27(2):101-117. doi: 10.1080/1354750X.2021.2016974. Epub 2021 Dec 31. Biomarkers. 2022. PMID: 34904497 Review.
-
Relationship Between Polycyclic Aromatic Hydrocarbons and Cardiovascular Diseases: A Systematic Review.Front Public Health. 2021 Dec 7;9:763706. doi: 10.3389/fpubh.2021.763706. eCollection 2021. Front Public Health. 2021. PMID: 34950626 Free PMC article.
References
-
- World Health Organization . WHO Fact Sheets; 2021. World Health Organisation Key Facts on Cardiovascular Diseases (CVDs)https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases...
-
- Forouzanfar M.H., Liu P., Roth G.A., Ng M., Biryukov S., Marczak L., et al. Global burden of hypertension and Systolic blood pressure of at least 110 to 115 mm Hg. JAMA, J. Am. Med. Assoc. 2017;317(6):648. 1990-2015.[Erratum appears in JAMA. 2017 Feb 14. PMID: 28114659] - PubMed
-
- Ruel M. Tackling the other Pandemic: the Rise in cardiovascular diseases. Can. J. Cardiol. 2022;38:849–851. doi: 10.1016/j.cjca.2022.06.001. - DOI
LinkOut - more resources
Full Text Sources